Inferra AI / Company / AUPH / Slides
Aurinia Pharmaceuticals — Presentation (company IR deck)
Aurinia Pharmaceuticals (AUPH) · 27 slides · Filed Oct 29, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All AUPH deck slides
Slide 1 — Third Quarter 2025 Update
® Third Quarter 2025 Update November 4, 2025
Slide 2 — Forward
® Forward - Loking Statements This presentation contains forward - loking statements within the meaning of aplicable U.S. securities law and forward - loking information within the meaning of aplicable Canadian securities law. We caution investors that forward - looking statements are based on manag asumptions as of the date of this presentation and involve substantial risks and uncertainties that could cause the actual outcomes to difer materialy from what we curently expect. These risks and uncertainties include, but are not limited to, those asociated with: total revenue; net product sales ; the timing, design and results of clinical studies; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Comision. Forward - loking statements in this presentation aply only as of the date made, and we undertake no obligation to update or revise any forward - loking statements to reflect subsequent events or circumstances. Aditional information related to Aurinia, including a detailed list of the risks and uncertainties afecting Aurinia and its busines, can be found in Aurinia‘s most recent Anual Report on Form 10 - K and its other public available filings available by accessing the Canadian Securities Administrators‘ Retrieval (SEDAR) website at w.sedarplus.ca or the U.S. Securities and E Electronic Document Gathering and Retrieval System (EDGAR) website at w.sec.gov/edgar , and on Aurinia‘s website at w.auriniapharma.com . 2
Slide 3 — Third Quarter 2025 Financial Highlights and Recent Busines Progres
® Third Quarter 2025 Financial Highlights and Recent Busines Progres 3 • Third quarter 2025 LUPKYNIS sales experienced continued momentum folowing last year‘s inclusion in American College of Rheu • LUPKYNIS sales guidance for 2025 raised for second time this year, to $265 milion to $270 milion • New LUPKYNIS data analyses reinforce LUPKYNI treatment of patients with lupus nephritis • Folowing positive Phase 1 results, aritinercept advances toward clinical studies in two autoimune diseases
Slide 4 — Financial Update
® Third Quarter 2025 Financial Update